Nuclera

About

Nuclera is a pioneering biotechnology company that specializes in rapid protein prototyping, aimed at transforming protein access for scientific research and drug discovery. Founded in 2013 by PhD students Michael Chen, Jiahao Huang, and Gordon Herling-McInroy at the University of Cambridge, the company emerged from the desire to overcome the inherent challenges of protein inaccessibility that hinder scientists' ability to progress in research. Nuclera's flagship technology, the eProtein Discovery™ system, provides an innovative solution that allows researchers to synthesize proteins more rapidly and efficiently. By utilizing advanced digital microfluidics and cell-free protein synthesis, Nuclera empowers scientists to turn DNA into purified, soluble, and biologically active proteins in as little as 48 hours. The eProtein Discovery™ platform facilitates simultaneous screening of multiple constructs and expression conditions, significantly accelerating the journey from concept to experimental validation. With state-of-the-art facilities located in Cambridge, UK, and Billerica, Massachusetts, Nuclera is committed to fostering advancements in protein sciences that ultimately lead to better human health outcomes. By streamlining workflows and optimizing protein production, Nuclera strives to ensure that protein prototyping is accessible directly at the benchtop.